ASX:AVH

Avita Medical is a commercial-stage regenerative medicine company focused on acute wound care and therapeutic skin restoration.

• Market Capitalization: ~AUD $170.81M – $174.95M
• Earnings Per Share (EPS): -AUD $0.452 (unprofitable)
• Performance (2026 YTD): +3.33% (though down roughly 27% over the past 12 months as the company works to scale and reduce cash burn).

Revenue Growth: Q1 2026 revenue reached $19.3 million USD, a 4% year-over-year increase and a 10% sequential increase from Q4 2025, showing gradual recovery following reimbursement and distribution disruptions in late 2025.